KLRA (Kailera Therapeutics) Treasury Stock: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRA Kailera Therapeutics Inc KLRA
11 GF Score
Price $17.32
! 1 Warning Sign
View Full Analysis

What is Kailera Therapeutics Treasury Stock?

Kailera Therapeutics KLRA +2.24% 11 Treasury Stock is $0.00 Mil as of Dec. 2025. GuruFocus rates KLRA with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Kailera Therapeutics's treasury stock for the quarter that ended in Dec. 2025 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Kailera Therapeutics Treasury Stock Historical Data

* Premium members only.

The historical data trend for Kailera Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics Treasury Stock Chart

Kailera Therapeutics Annual Data
Trend Dec24 Dec25
Treasury Stock
0.00 0.00

Kailera Therapeutics Semi-Annual Data
Dec24 Dec25
Treasury Stock 0.00 0.00
KLRA
11GF Score
Kailera Therapeutics Inc KLRA
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kailera Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $0.00 Mil mean?
Kailera Therapeutics (KLRA) has a Treasury Stock of $0.00 Mil as of Dec. 2025. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Kailera Therapeutics and its competitors.
Is Kailera Therapeutics' Treasury Stock too high?
Kailera Therapeutics' current Treasury Stock is $0.00 Mil. Overall, Kailera Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' Treasury Stock compare to VCEL and NUVB?
Kailera Therapeutics' Treasury Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Kailera Therapeutics and its competitors. Kailera Therapeutics's current Treasury Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current Treasury Stock of $0.00 Mil. The current Treasury Stock is $0.00 Mil. Kailera Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current Treasury Stock is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kailera Therapeutics Business Description

Address 180 Third Avenue, 4th Floor, Waltham, MA, USA, 02451
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
11GF Score

Get the complete analysis for KLRA

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.32
Price